MiMedx Group Inc MDXG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MDXG is a good fit for your portfolio.
News
-
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
-
MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit
-
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
-
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
-
MIMEDX Introduces E-Commerce and Account Management Platform
-
MIMEDX Announces Appointment of Two New Independent Directors
-
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
-
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
Trading Information
- Previous Close Price
- $6.25
- Day Range
- $6.18–6.32
- 52-Week Range
- $3.53–9.27
- Bid/Ask
- $6.26 / $6.30
- Market Cap
- $925.35 Mil
- Volume/Avg
- 604,808 / 831,035
Key Statistics
- Price/Earnings (Normalized)
- 66.02
- Price/Sales
- 2.85
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 895
- Website
- https://www.mimedx.com
Comparables
Valuation
|
Metric
|
MDXG
|
ANGO
|
ATEC
|
|---|---|---|---|
Price/Earnings (Normalized) | 66.02 | — | — |
Price/Book Value | 6.42 | 1.07 | 22.71 |
Price/Sales | 2.85 | 0.72 | 3.20 |
Price/Cash Flow | 17.15 | — | — |
Price/Earnings
MDXG
ANGO
ATEC
Financial Strength
|
Metric
|
MDXG
|
ANGO
|
ATEC
|
|---|---|---|---|
Quick Ratio | 2.95 | 1.49 | 1.86 |
Current Ratio | 3.57 | 2.29 | 2.86 |
Interest Coverage | 5.74 | — | −10.23 |
Quick Ratio
MDXG
ANGO
ATEC
Profitability
|
Metric
|
MDXG
|
ANGO
|
ATEC
|
|---|---|---|---|
Return on Assets (Normalized) | 12.48% | −2.40% | −9.89% |
Return on Equity (Normalized) | 123.45% | −3.15% | — |
Return on Invested Capital (Normalized) | 42.32% | −2.98% | −9.94% |
Return on Assets
MDXG
ANGO
ATEC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bsjjbmcnj | Rftp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xpxgsskb | Tstypl | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sdwwnqhj | Qmsgz | $97.8 Bil | |
MRNA
| Moderna Inc | Vhkwmqbb | Ffp | $41.3 Bil | |
ARGX
| argenx SE ADR | Mjfvmnhm | Tslcn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Tyglrhrm | Jblqy | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nvyzqmc | Nftrhzq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ltnwvzhvf | Xwkftj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ppnqhhcw | Sxrslk | $12.5 Bil | |
INCY
| Incyte Corp | Cvmmzwsmx | Nszbd | $11.6 Bil |